The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US in 1952 and still privately owned, the network has a presence in over 120 countries, employing over 8,600 people and generating annual revenues in excess of $3.4 billion. It is a leader pain medicine and is also present in the core therapeutic areas of respiratory, oncology and biosimilars.